School of Pharmacy


Prof. Moein Moghimi has published a paper in Advanced Drug Delivery Reviews

"CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs".



Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective strategy to combat cancer.  Today, CAR T-cell therapy has proven successful in the treatment of haematological malignancies and the first CD19 CAR T-cell products has already entered the market.  This success is expanding CAR design for broader malignancies including solid tumours.  Nevertheless, CARs such as those built on antigen-specific single chain antibody variable fragment (scFv) may induce some adverse effects.  Here, we briefly review CAR T-cell bioengineering and discuss selected important initiatives for improved T-cell reprogramming, function and safety.  In this respect, we further elaborate on unconventional CARs structured on single variable domain of heavy chain (VHH) antibodies (single-domain antibodies) as an alternative to scFv, because of their interesting immunological and physicochemical characteristics and unique structure, which shows a high degree of homology with human VH3 gene family.

The full paper can be found here

Prof. Moein Moghimi

published on: 18 April 2019